Skip to main content

Thank you for visiting nature.com. You are using a browser version with limited support for CSS. To obtain the best experience, we recommend you use a more up to date browser (or turn off compatibility mode in Internet Explorer). In the meantime, to ensure continued support, we are displaying the site without styles and JavaScript.

  • In Brief
  • Published:

Infectious disease

New target for antimalarials

Nature Reviews Drug Discovery volume 14, page 602 (2015)Cite this article

Subjects

An attractive strategy to limit the evolution of drug-resistant malaria-causing parasites is to target host factors that are essential for parasite invasion. Now, Zenonos et al. describe the development of a high-affinity recombinant chimeric antibody targeting the erythrocyte receptor basigin 1, which is essential for invasion in all tested strains of Plasmodium falciparum. The novel antibody prevented invasion of erythrocytes by multiple P. falciparum parasite lines in vitro, and cleared blood-stage parasites without side effects in a mouse P. falciparum infection model.

This is a preview of subscription content, access via your institution

Access options

Buy this article

  • Purchase on SpringerLink
  • Instant access to the full article PDF.

USD 39.95

Prices may be subject to local taxes which are calculated during checkout

References

  1. Zenonos, Z. P. et al. Basigin is a druggable target for host-oriented antimalarial interventions. J. Exp. Med. 212, 1145–1151 (2015)

    Article  CAS  PubMed Central  Google Scholar 

Download references

Authors
  1. Sarah Crunkhorn
    View author publications

    Search author on:PubMed Google Scholar

Rights and permissions

Reprints and permissions

About this article

Check for updates. Verify currency and authenticity via CrossMark

Cite this article

Crunkhorn, S. New target for antimalarials. Nat Rev Drug Discov 14, 602 (2015). https://doi.org/10.1038/nrd4720

Download citation

  • Published:

  • Issue date:

  • DOI: https://doi.org/10.1038/nrd4720

Search

Advanced search

Quick links

Nature Briefing: Translational Research

Sign up for the Nature Briefing: Translational Research newsletter — top stories in biotechnology, drug discovery and pharma.

Get what matters in translational research, free to your inbox weekly. Sign up for Nature Briefing: Translational Research